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IMPORTANCE Whether and under which conditions D-cycloserine (DCS) augments the effects
of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and
posttraumatic stress disorders is unclear.
OBJECTIVE To clarify whether DCS is superior to placebo in augmenting the effects of
cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress
disorders and to evaluate whether antidepressants interact with DCS and the effect of
potential moderating variables.
DATA SOURCES PubMed, EMBASE, and PsycINFOwere searched from inception to February
10, 2016. Reference lists of previous reviews andmeta-analyses and reports of randomized
clinical trials were also checked.
STUDY SELECTION Studies were eligible for inclusion if they were (1) double-blind randomized
clinical trials of DCS as an augmentation strategy for exposure-based cognitive behavior
therapy and (2) conducted in humans diagnosed as having specific phobia, social anxiety
disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, or
posttraumatic stress disorder.
DATA EXTRACTION AND SYNTHESIS Raw data were obtained from the authors and quality
controlled. Data were ranked to ensure a consistent metric across studies (score range,
0-100). We used a 3-level multilevel model nesting repeatedmeasures of outcomes within
participants, who were nested within studies.
RESULTS Individual participant datawere obtained for 21 of 22 eligible trials, representing 1047
of 1073 eligible participants.When controlling for antidepressant use, participants receiving
DCS showed greater improvement frompretreatment to posttreatment (mean difference,
−3.62; 95%CI, −0.81 to −6.43; P = .01; d = −0.25) but not frompretreatment tomidtreatment
(mean difference, −1.66; 95%CI, −1.60 to 4.92; P = .32; d = −0.14) or frompretreatment to
follow-up (mean difference, −2.98, 95%CI, −0.03 to 5.99; P = .05; d = −0.19). Additional
analyses showed that participants assigned to DCSwere associatedwith lower symptom
severity than those assigned to placebo at posttreatment and at follow-up. Antidepressants did
notmoderate the effects of DCS. None of the prespecified patient-level or study-level
moderators was associatedwith outcomes.
CONCLUSIONS AND RELEVANCE D-cycloserine is associated with a small augmentation effect
on exposure-based therapy. This effect is not moderated by the concurrent use of
antidepressants. Further research is needed to identify patient and/or therapy characteristics
associated with DCS response.
JAMA Psychiatry. doi:10.1001/jamapsychiatry.2016.3955
Published online January 25, 2017.
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A nxiety,obsessive-compulsive, andposttraumatic stressdisorders constitute themost prevalent groupofmen-tal disorders, collectively affecting up to 30% of indi-
viduals at somepoint in their lives.1 These conditions contrib-
ute significantly to theglobal burdenofdisease anddisability-
adjusted life-years.2
First-line treatments for these conditions include cogni-
tive behavior therapy (CBT), typically involving exposure to
feared stimuli,3-9 and medication, primarily selective seroto-
nin reuptake inhibitors.3-10While there is ample support for the
efficacyofCBTandselectiveserotoninreuptakeinhibitors,asub-
stantial proportion of patients do not achieve sufficient symp-
tomrelief andrequireadditional long-termcare. Ingeneral, the
combinationofthesetreatmentmodalities isnotsuperior toCBT
alone in the long run11-13 and may in fact have deleterious ef-
fects and result in increased relapse rates after discontinuation
ofmedication.14,15 In lightof these results, researchershavebe-
gun exploring other ways to augment the effects of CBT.16,17
One promising strategy is the administration of D-
cycloserine (DCS), a partialN-methyl-D-aspartate agonist that
facilitates fear extinction in animals and reduces returnof fear
when given before or shortly after extinction training.16 De-
spite several initial trials showing promising results in hu-
manswithanxietydisorders,18-20 larger trials conductedwithin
the past 5 years21,22 have produced mixed results.23-26 Re-
search suggests that DCS may only enhance CBT under cer-
tain conditions.21,22,27 Variables, such as the number of CBT
sessions, thedoseandnumberofDCSadministrations, the tim-
ing of drug administration, the success of the exposure ses-
sions, or compliancewithbetween-sessionhomeworkassign-
ments,may also contribute to the conflicting results obtained
to date.26 Further, a large trial in obsessive-compulsive
disorder22 found a significant interaction effect betweenDCS
and antidepressant medication in a post hoc analysis; con-
comitant antidepressants impaired treatment response in pa-
tients randomized to DCS but not in patients randomized to
placebo. These results, which are consistent with the animal
literature,28-30 suggest that DCSmay only be indicated in pa-
tients who are not receiving antidepressants, but these re-
sults require replication.
Theprimaryaimsof this 1-stage individual-participantdata
(IPD)meta-analysis were to help clarifywhether DCS is supe-
rior toplacebo inaugmenting theeffectsofCBTforanxietydis-
orders after adjusting for antidepressant use and to evaluate
whether antidepressants interact with DCS to reduce its fa-
cilitatingeffectsonCBT. Secondaryaimswere toexaminehow
the following variables affect or moderate the effects of DCS:
age, sex, age group (child vs adult), primary diagnosis, num-
ber of exposure sessions, DCS dose, timing of administration,
and number of DCS administrations. Additionally, we exam-
inedwhether DCS led to faster improvement of symptoms by
examining the effect of DCS vs placebo at midtreatment. In-
dividual-participantdatameta-analysesareconsideredthegold
standardofmeta-analysis andoffer anumberof important ad-
vantages over traditional meta-analyses that rely on sum-
marystatistics, including thebetter controlofpatient-level and
study-level confounders and increasedpower fordetecting in-
teraction effects and subgroup analyses.31,32
Methods
Protocol and Registration
Thereviewwasconductedusing thePreferredReporting Items
for Systematic Reviews andMeta-Analyses of Individual Par-
ticipant Data (checklist and protocol).31
Eligibility Criteria
Studies were eligible for inclusion if they were (1) published
or unpublished double-blind, randomized, placebo-
controlled trials of DCS as an augmentation strategy for CBT
or behavior therapy incorporating exposure or exposurewith
response prevention techniques or experimental studies in-
cluding a single-exposure session and (2) conductedwith hu-
mans with a diagnosis of specific phobia, social anxiety dis-
order, panic disorderwith orwithout agoraphobia, obsessive-
compulsivedisorder, or posttraumatic stress disorder. For the
specific phobia studies, the impairment/interference crite-
rion required for the diagnosis waswaived to allow the inclu-
sion of fearful individuals who were not significantly im-
paired given the sporadic appearance of the phobic stimulus
in their daily lives.
Information Sources and Search
Twoauthors (B.M.andA.P.-V.) conductedan independentsys-
tematic, 2-step literature search to identify relevant articles.
First, PubMed,EMBASE, andPsycINFOwere searched fromin-
ception to February 10, 2016. Second, manual searches of the
reference listsofeligiblearticlesandpreviousreviewsandmeta-
analyses of aggregate data were performed. Additionally, key
authors in the field were contacted for unpublished data.
The searchwasperformedusing searchalgorithms includ-
ing the terms D-cycloserine [and related terms]; CBT, behav-
ior therapy, or exposure therapy [and related terms]; and any
of the diagnoses of interest (eMethods 1 in the Supplement).
No restrictions were set. Results from the 3 blocks were com-
bined and duplicates removed.
Study Selection and Data Collection Processes
Eligibility of trials was assessed independently by 2 authors
(B. M. and A. P.-V.). Any differences in opinion regarding eli-
gibility were resolved by discussion.
Key Points
Question Does D-cycloserine (DCS) augment the effects of
exposure-based therapy for anxiety, obsessive-compulsive, and
posttraumatic stress disorders?
Findings In this meta-analysis of individual participant data in 21
systematic reviews and trials, when controlling for antidepressant
use, participants receiving DCS showed greater improvement from
pretreatment to posttreatment but not from pretreatment to
midtreatment or from pretreatment to follow-up. Effect sizes were
small, and antidepressants did not moderate the effects of DCS.
Meaning Further research is needed to identify patient and/or
therapy characteristics associatedwith theDCS augmentation effect.
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Corresponding authors of all eligible studies were con-
tacted and informed via email. Those who were able to con-
tributewereaskedtoprovideanonymizeddata fromtheir stud-
ies using a prespecified template. Data from the individual
studies provided were quality controlled and subsequently
merged for analysis. For those studieswhere IPDwasnotavail-
able, data items were extracted from the publications.
Data Items
The requested IPD included the anonymous participant num-
ber, sex, age, condition (DCS vs placebo), number of DCS or
placebo administrations, time of pill administration (ie, num-
ber of minutes before/after the exposure sessions), DCS dose
(in milligrams), concomitant antidepressant medication
(present/absent, drug name, and dose), number of CBT ses-
sions, and outcomes at major treatment time points (base-
line, midtreatment, posttreatment, and follow-up) as mea-
sured by the primary outcome measure stipulated by the
authors in each individual study. Because different primary
outcome measures had different score ranges and data distri-
butions across studies, outcome measures were harmonized.
Specifically, we transformed the original data into ranked
data to ensure a common metric across studies (score range,
0-100). This is described in detail in the eMethods 2 in the
Supplement.
Individual Participant Data Integrity
Two authors (B. M. and L. F. C.) independently assessed IPD
data sets, with queries resolved by a third author (D.M.-C.).
The data were checked with respect to range, missing or
extreme values, errors, and consistency with the published
data. Trial details, such as randomization methods and inter-
vention details, were crosschecked against the original publi-
cations. Inconsistencies or missing data were discussed and
resolved with the collaborators. Each trial was checked indi-
vidually, and the trial data were sent to the original authors
for verification.
Risk of Bias Assessment in Individual Studies
and Across Studies
Eligibility criteria were prospectively defined, and all rel-
evant published and unpublished trials were sought to avoid
bias. We checked for unusual allocation patterns or distribu-
tionsof participant characteristics andcheckedwhether there
were trials with inappropriate allocation. We established
whether any randomized participant data were not included
in the data sets (eg, if authors conducted analyses based on
completers only, we requested all data on randomized pa-
tients in order to perform intent-to-treat analyses). We ex-
cluded any nonrandomized participants from the data sets.
The Cochrane Collaboration Tool for Assessing Risk of
Bias33,34 was used (post hoc) to explore possible bias in the
individual studies.
Synthesis Methods
We conducted a 1-stage IPDmeta-analysis. We used a 3-level
multilevel model (MLM) nesting repeated measures of out-
comewithinparticipants,whowerenestedwithinstudies.Our
MLManalyses, performedusingHierarchical Linear andNon-
linear Modeling version 7.01 (Scientific Software Interna-
tional Inc),were coded toperform theMLMequivalent of a re-
peated-measures analysis of covariance, allowing slopes and
intercepts to vary between studies and retaining all partici-
pants even if theymissed assessments or dropped out (ie, in-
tent-to-treat analyses). α Values were 2-tailed, and statistical
significance was set at .05.
Our primary analyses examined (1) whether DCS led to
greater improvement than placebo after adjusting for antide-
pressant use and (2) whether antidepressant use moderated
the effect of treatment condition (DCS vs placebo) on out-
come. Planned secondary analyses examined other possible
moderators of the treatment conditioneffect (listed in thepre-
vious section). Post hoc, it was determined that sample size,
year of publication, and study quality (risk of bias)were addi-
tional variables that were available and may moderate treat-
ment condition effects. Thus, they were added to the mod-
erator analysis.
To model a repeated-measures analysis of covariance in
MLM, the growth curve consisted of 3 dummy variables that
modeled the change frompretreatment tomidtreatment, pre-
treatment to posttreatment, and pretreatment to follow-up.
Eachmoderator, including antidepressant use, was tested by
adding the moderator and the moderator × treatment condi-
tion interaction as predictors of the intercept and each of the
3 “slopes” (pretreatment to midtreatment, pretreatment to
posttreatment,andpretreatment to follow-up).Moderatorvari-
ables were converted to z scores to facilitate comparison be-
tween moderators and to center them at their mean. Treat-
ment groupwas also centered at its mean. The coding for the
dichotomousvariableswas as follows: group: placebo = 0and
DCS = 1; sex: men = 0 and women = 1; child vs adult studies:
child = 0andadult = 1;anddiagnosis:eachdiagnosiswascoded
as 1 for that diagnosis and as 0 for other diagnoses. To calcu-
late the timingof administrationvariable, the start timeof the
sessionwas subtracted from the timeof the administration of
the pill, with the result coded in minutes (negative numbers
onthisscale indicate thatDCSwasadministeredbefore thestart
of the session, while positive numbers indicate that DCS was
administered after the start of the session). Standardized ef-
fect sizes (theMLMequivalent ofCohend)were calculated for
all significant effects using the techniques developed by
RaudenbushandXiao-Feng35orFeingold,36asappropriate.Be-
cause clinicians and researchers may be specifically inter-
ested in the effects of DCS for each type of diagnosis, sub-
group analyses were conducted for each primary diagnosis
using identical models.
Power analyses, performed using Optimal Design, indi-
cated greater than0.80power todetect small effect sizes (Co-
hen d = 0.20) for individual-level effects, including the treat-
mentgroupeffect and individual-levelmoderators (eg, sexand
age). On the other hand, because there were only 21 studies,
the power to detect even a large effect size (d = 0.80) for the
study-level moderators/predictors (eg, sample size and diag-
nosis) was only approximately 0.70 for single predictors (eg,
samplesize)andonlyabout0.40fordiagnosis,whichwascom-
prised of 4 dummy variables.
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Results
Study Selection and IPDObtained
Of that 377 studies that were initially identified and analyzed
for eligibility, 22 studiesmet inclusion criteria (Figure 1). The
22eligible trials included 1073participants, including 124with
specific phobia, 291with social anxietydisorder, 77withpanic
disorder with or without agoraphobia, 292 with obsessive-
compulsive disorder, and 289 with posttraumatic stress
disorder.18-22,37-53 Study characteristics of the 22 eligible stud-
ies are presented in eTable 1 in the Supplement.
We were able to obtain IPD from 21 of these 22 studies.
Data from 26 participants included in one posttraumatic
stress disorder study50 could not be included because the
local ethics committee did not allow data sharing. Therefore,
the final data set included 1047 patients (523 receiving DCS
and 521 receiving placebo; for 3 additional patients, the group
allocation variable was missing), which, to our knowledge,
represents 97.6% of the available data. Four of 21 studies
were pediatric. The mean (SD) age of the whole sample was
32.1 (13.5) years. The sample was evenly split by sex, with 516
women (49.4%). About one-quarter of the sample (275
[26.9%]) were receiving antidepressants (eTable 2 in the
Supplement). The mean (SD) number of treatment sessions
was 7.6 (4.5).
IPD Integrity and Risk of BiasWithin Studies
Discrepancies between the provided IPD and the original
reports were found in 16 of 21 studies. Twenty-nine mis-
matches were found, most of which were related to different
numbers of patients receiving antidepressant medication
reported in the publication vs the data set. All discrepancies,
except for a mismatch on the medication breakdown in one
study (where we assumed that the actual data set was cor-
rect) were successfully resolved by correspondence with the
authors.
Authors of 5 of the included studieswere contacted to re-
questmissing data. Allmissing datawere provided except for
the age variable in one of the studies.
Correspondingauthorsof6of theeligible studieswerecon-
tacted to request data on all randomized participants be-
cause initially only information on completers had been pro-
vided. Data were received for 31 noncompleters who had
originally been omitted from the data sets. Additionally, one
of the data sets included 2 nonrandomized participants who
were excluded prior to analysis.
Results of Individual Studies
Datawere obtained for all participantswhowere initially ran-
domized in each of the studies for which IPD were available.
Between-group (DCSvsplacebo)Cohend effect sizes and95%
CIs at posttreatment for each individual study based on raw
data are shown in eTable 3 in the Supplement.
Results of Syntheses (Primary Aim)
We identified 11 different primary outcomes measures in the
included studies (eTable 1 in the Supplement). As expected,
the different outcomemeasures haddifferent ranges anddis-
tributions (eFigure in theSupplement), and therefore, thedata
were transformed to ensure a common measurement across
studies (eMethods 2 in the Supplement).
Initial exploratory analyses to determine the overall ef-
fect of DCS vs placebo showed that improvementwas greater
in those who received DCS than those who received placebo
frompretreatment toposttreatment (difference,−3.93;95%CI,
−1.16 to −6.70; P = .006, d = −0.27) and frompretreatment to
follow-up (difference, −3.32; 95% CI, −0.34 to −6.30; P = .03,
d = −0.21) but not frompretreatment tomidtreatment (differ-
ence, −1.69; 95% CI, −1.51 to −4.89; P = .30) (eTable 4 in the
Supplement). Theseanalyses also showed thatparticipants re-
ceivingDCShad lower symptomseverity thanparticipants re-
ceiving placebo at posttreatment (difference, −3.34; 95% CI,
−1.12 to −5.56; P = .004, d = −0.22) and at follow-up (differ-
ence, −2.73, 95%CI, −0.25 to −5.21;P = .03;d = −0.18) (eTable
4 in the Supplement).
Figure 1. PRISMA Individual-Participant Data (IPD) Flowchart
for the Study
0 Additional studies identified
through other sources including
contact with researcher
376 Studies after duplicates removed 
376 Studies screened for eligibility
22 Studies for which IPD were sought 
0 Eligible studies for which IPD were
not sought  
97 PubMed
333 Embase
124 PsycINFO
Studies identified through database
searching:
354 Studies excluded:
282 Not randomized clinical trial
34 Not on disorders of interest
14 Not on humans
12 Not testing D-cycloserine in
addition to cognitive
behavior therapy
9 Secondary analysis 
2 Without a clinical diagnosis
1 Not double-blinded
21 Studies for which IPD were
provided
1047 Participants for whom
data were provided
0 Participants for whom
no data were provided
IPD (report for each main outcome)
21 Studies included in analysis
1047 Participants included in analysis
0 Participants excluded
Aggregate data (report for each main
outcome)
22 Studies included in analysis
1073 Participants included in analysis
0 Participants excluded
1 Study for which IPD were not
provided (ethical approval to share
data not granted)
26 Participants
22 Studies for which aggregate data
were available
1073 Participants
Research Original Investigation D-Cycloserine Augmentation of Cognitive Behavior Therapy
E4 JAMAPsychiatry Published online January 25, 2017 (Reprinted) jamapsychiatry.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/0/ by a Boston University User  on 01/25/2017
Copyright 2017 American Medical Association. All rights reserved.
To investigateprimaryaim1,weranthis sameanalysis con-
trolling for antidepressant use as a moderator of the DCS ef-
fects (Table 1). Participants receiving DCS showed greater im-
provement than those receivingplacebo frompretreatment to
posttreatment (difference, −3.62; 95% CI, −0.81 to −6.43,
P = .01, d = −0.25), but not from pretreatment to midtreat-
ment (difference, −1.66, 95% CI, −1.60 to 4.92; P = .32;
d = −0.14)or frompretreatment to follow-up(difference,−2.98;
95% CI, −0.03 to 5.99; P = .05; d = −0.19) (Table 1; Figure 2).
Additionalposthocanalyses also revealed thatparticipants re-
ceivingDCSevidenced lower symptomseverity than those re-
ceiving placebo at bothposttreatment (difference, −3.19; 95%
CI, −0.95 to −5.43; P = .006; d = −0.21) and at follow-up (dif-
ference, −2.54; 95% CI, −0.04 to −5.04; P = .05; d = −0.16).
Thesamemodelwasusedtoaddressprimaryaim2.Results
showed that antidepressant use did not moderate any of the
effects ofDCSonoutcome (Table 2). However,wedid find that
regardless of randomized treatment condition, participants
taking antidepressants improved more from pretreatment to
follow-up than those not taking antidepressants (difference,
−4.32; 95%CI, −0.64 to −8.01; P = .02, d = −0.28) (Table 1).
Moderator Analyses (Secondary Aim)
The randomeffects for the improvement frompretreatment to
midtreatment(χ210 = 144.02;P < .001),pretreatmenttoposttreat-
ment(χ210 = 150.83;P < .001),andpretreatmenttofollow-up(χ210
= 1102.70;P < .001)weresignificant, indicatingsignificantvari-
ability in the amount of improvement between studies, hence
suggesting theexistenceofpossiblemoderators.Wefirstexam-
ined eachmoderator separately. We then included all the sig-
nificant moderators and predictors in a final, composite mul-
timoderator analysis. Onemoderatorwas relevant toDCSpar-
ticipants only (DCS dose) and could not be estimated as a
moderator in thefull samplebecause itwas0forallplacebopar-
ticipants. Hence, we could analyze DCS dose only as a predic-
tor and not as amoderator of outcome in a separate analysis.
Results from the individual moderator analyses are pre-
sented inTable2.Significantmoderators in the individualmod-
erator analyses were then included in the multimoderator
analysis. Only 1 significant moderator emerged: year of pub-
lication. Specifically, themore recent the study, the smaller the
difference between DCS and placebo for pretreatment to fol-
low-up improvement (b = 4.02; 95% CI, 0.59-7.45; P = .02,
d= 0.26). Additional post hoc analyses showed that the over-
all score in theCochraneCollaborationTool forAssessingRisk
of Bias for each individual study (eResults and eTables 5 and
6 in the Supplement) was not a significant moderator of any
of the DCS effects (Table 2).
Theanalysisof theDCS-relevantpredictor,performedusing
only the DCS subsample, showed that DCS dosage was highly
skewed(skewness = 3.89).While428of523participants (81.8%)
received50mgofDCS, some received250mgor even500mg.
To reduce skewness to acceptable levels (<1.0),54 we used the
inversetransformation,54whichreducedskewnessto−0.31.The
analysis of the transformedDCSdosage showed that itwasnot
associated with the outcome (Table 2).
Risk of Bias Across Studies
Toourknowledge, thismeta-analysis includes97.6%of all eli-
gible data. The only missing study50 failed to find an advan-
tageofDCSvsplacebo in individualswithposttraumatic stress
Table 1. Multilevel Model Coefficients for the Effect of D-Cycloserine
vs Placebo in the Augmentation of Exposure-Based Cognitive-Behavior
Therapya (Primary Aims 1 and 2)
Predictor
Regression
Coefficient (SE) P Value
Intercept 50.33 (0.97) <.001b
Group (DCS/placebo)c 0.43 (1.07) .69
Antidepressants 2.39 (1.31) .08
Baseline severity 0.60 (0.04) <.001b
Time pretreatment to midtreatment −24.39 (3.95) <.001b
Time pretreatment to posttreatment −35.05 (3.85) <.001b
Time pretreatment to follow-up −36.40 (3.11) <.001b
Group × antidepressants 0.80 (2.43) .74
Group × time pretreatment to
midtreatment
−1.66 (1.67) .32
Group × time pretreatment to
posttreatment
−3.62 (1.44) .01b
Group × time pretreatment to follow-up −2.98 (1.54) .05
Antidepressants × time pretreatment
to midtreatment
−0.81 (2.19) .71
Antidepressants × time pretreatment
to posttreatment
−2.01 (1.81) .27
Antidepressants × time pretreatment
to follow-up
−4.32 (1.89) .02b
Group × time pretreatment to
midtreatment × antidepressants
−2.23 (3.99) .58
Group × time pretreatment to
posttreatment × antidepressants
−3.67 (3.28) .26
Group × time pretreatment to
follow-up × antidepressants
1.19 (3.51) .73
Abbreviation: DCS, D-cycloserine.
a Antidepressants were included in themodel as an a priori moderator.
b These effects were also significant in the final multimoderator analysis.
c Group was coded as placebo = 0 and DCS = 1.
Figure 2. Group by Time Interaction Effects on the Transformed
Primary OutcomeMeasurea
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disorder. In that study, exposure therapy plus placebo per-
formed significantly better than exposure therapy plus DCS,
leading to a potential bias in favor of DCS owing to the omis-
sion of that study.
Additional Analyses
For more detailed information on the effect of DCS by diag-
nosis, we ran our primary analysis separately for each diag-
nosis (eTable 7 in theSupplement). TheadvantageofDCSover
placebowas only significant for thosewith social anxiety dis-
order (eTable 5 in the Supplement). Antidepressants signifi-
cantlymoderatedDCS effects only for participantswithpanic
disorder with or without agoraphobia, which made up the
smallestdiagnosis sample inourmeta-analysis (n = 77) and in-
cluded only 2 studies (eTable 1 in the Supplement).
Sensitivity Analyses
We reran our models excluding the single-session studies by
Gutner et al38 and Rodebaugh et al,41 which were not treat-
ment studies but experimental in nature. In the analysis con-
trolling for antidepressant use as a moderator of the DCS ef-
fects (primary aim 1), participants receivingDCSdidnot show
greater improvement frompretreatment toposttreatment (dif-
ference,−2.85;95%CI,−5.91 to0.21;P = .06;d = −0.21) (eTable
8 in theSupplement).However, effect sizeswere similar to the
original analyses (d = −0.21 vsd = −0.25). Antidepressant use
did not moderate any of the effects of DCS on outcome (pri-
mary aim 2).
Additionally,we repeated the analyses excludingonly the
study by Gutner et al,38 whichwas the only one including pa-
tientswhomaynothavemet the impairment/interference cri-
terion for specific phobia. Results after the exclusion of this
trialwerevirtually identical to thosereportedfor thefull sample
(eTable 8 in the Supplement).
Discussion
Themain findingof this 1-stage IPDmeta-analysiswas thatDCS
showed a statistically significant advantage over placebo at
posttreatment, regardless of the inclusion of treatment with
antidepressants in themodel. This advantage was small (less
than4points ona0-100 scale;d = −0.25). Less consistent evi-
dence was found for the advantage of DCS at follow-up. Fur-
thermore, themultimoderatoranalysis revealed thatonlypub-
lication year was significant, suggesting that more recent
studies tendedtoshowsmallerdifferences in improvementbe-
tweenDCS andplacebo frompretreatment to follow-up (0.26
SDs less improvement for each additional year).
Theaccelerationof treatment effects observed in some in-
dividual trials atmidtreatment21,55 couldnot be confirmedbe-
cause there were no significant midtreatment effects. Our
analyses also failed to confirm the hypothesis that concomi-
tant antidepressantmedicationwouldmoderate the effects of
DCS, as initially suggested by the animal literature28,29 and a
2015 human trial.22
Thenumberof treatment sessionsdidnotmoderate treat-
ment outcomes. It has been suggested that DCS may offer
greater advantage vs placebo when brief treatments are used
because the placebo-treated patients have less chances to
“catch up” with the DCS-treated patients in brief treat-
ments.27,56 Our analysis did not support this hypothesis but
suggested that the small benefits of DCS at posttreatment are
attenuated during follow-up.
The number of DCS pill administrations was not associ-
ated with the degree of improvement at any time. This find-
ing is not consistent with the concern that DCS efficacy may
decrease with increasing numbers of administrations.24
Neither the timeof administrationnor thedoseofDCShad
aneffect on theoutcomes, although therewas relatively small
variability in the data. Most trials administered the drug ap-
proximately 1hourbefore theexposure session, andmostpar-
ticipants received 50-mg doses.
Although DCSmay exert its effects by enhancing fear ex-
tinction retention, studies have not limited inclusion to par-
ticipants with extinction consolidation deficits. Therefore,
weak effects across trials are perhaps unsurprising. Similarly,
DCS has been administered in these studies independent of
within-session learningexperiences, anotableweaknessgiven
the possibility that DCSmay enhance fearmemory reconsoli-
dation under certain conditions.57 Extinction learning varies
across sessions and patients, and accordingly, DCS may have
inadvertently interfered with exposure efficacy in some pa-
tients and facilitated its efficacy in others.57,58
Strengths and Limitations
Amajor strength of this studywas that we could obtainmore
than 97% of all eligible raw data, which greatly surpasses the
greater than 90% of eligible participants that has been sug-
gestedas a suitable target to achieve.59Apower calculation re-
vealed that, with our combined sample size, we had greater
than 80% power to detect an effect size as small as a Cohen d
value of 0.20 for the treatment effects and individual-level
moderators.This representsasubstantial improvementonpre-
vious aggregate-data meta-analyses,23-26,60 which were only
powered to detect large effect sizes.
This study also had limitations. We had less power to de-
tect study-levelmoderators/predictorsandfor subgroupanaly-
ses. Similarly, there have only been 4 studies using pediatric
samples, which limits the generalizability of our results to
youngerpopulations.Another limitation is thatdifferent stud-
iesuseddifferentoutcomemeasures, and for this reason, these
hadtobetransformedintorankedscores toensureasinglemet-
ric across studies. Finally,wecouldnot examine in-sessionex-
periences as possible moderators of DCS efficacy. For ex-
ample, fear at the end of an exposure therapy session has
emergedas 1possible important variable57 because it hasbeen
shown tomoderateDCSefficacy in 2 studies58,61 aswell as the
efficacy of 2 other pharmacological enhancement strategies
(yohimbine62 and methylene blue63).
Conclusions
We found evidence supporting the short-term superiority of
DCS vs placebo in the augmentation of exposure-based CBT
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for anxiety-relateddisorders andmixed support for themain-
tenance of these benefits at follow-up.While statistically sig-
nificant, the effect sizeswere small. Concomitant antidepres-
sant medication did not significantly moderate the effects of
DCS. None of the prespecified patient-level (eg, age and sex)
or study-level (eg, primarydiagnosis, numberof exposure ses-
sions,DCSdose, timingof administration, andnumber ofDCS
administrations)moderatorswere clearly associatedwithout-
comes.The limitationsofprevious studies and lessons learned
over the past decade call for a next stage of research examin-
ing the efficacy of DCS and other augmentation strategies for
facilitatingexposure therapy,which specifically examines tar-
geted administration as guided by theory and basic research
findings.27,64,65
ARTICLE INFORMATION
Published Online: January 25, 2017.
doi:10.1001/jamapsychiatry.2016.3955
Author Affiliations: Centre for Psychiatry
Research, Department of Clinical Neuroscience,
Karolinska Institutet, Stockholm, Sweden (Mataix-
Cols, Fernández de la Cruz, Andersson, Pérez-Vigil,
Rück); Stockholm Health Care Services, Stockholm
County Council, Stockholm, Sweden (Mataix-Cols,
Rück); Institute of Psychiatry, Psychology, and
Neuroscience, Department of Psychology, King’s
College London, London, United Kingdom
(Monzani); Department of Psychology, Southern
Methodist University, Dallas, Texas (Rosenfield);
Unit of Biostatistics, Institute of Environmental
Medicine, Karolinska Institutet, Stockholm, Sweden
(Frumento); Center for Anxiety Disorders Overwaal,
Institution for IntegratedMental Health Care Pro
Persona, Nijmegen, the Netherlands (de Kleine,
Hendriks, vanMinnen); Behavioral Science
Institute, NijCare, Radboud University Nijmegen,
Nijmegen, the Netherlands (de Kleine, Hendriks,
vanMinnen); Department of Psychiatry, Weill
Cornell Medical College, New York, New York
(Difede, Lee, Wyka); Department of Psychiatry and
Behavioral Sciences, Emory University School of
Medicine, Atlanta, Georgia (Dunlop, Gerardi,
Rothbaum, Davis); School of Applied Psychology,
Griffith University, Brisbane, Queensland, Australia
(Farrell, Waters); Menzies Health Institute of
Queensland, Brisbane, Queensland, Australia
(Farrell, McConnell, Waters); Department of
Psychiatry, Massachusetts General Hospital, Boston
(Geller, Wilhelm); Harvard Medical School, Boston,
Massachusetts (Geller, Ressler, Wilhelm); Brain and
Mind Research Institute, Central Clinical School,
University of Sydney, Sydney, New SouthWales,
Australia (Guastella); Department of Psychological
and Brain Sciences, Boston University, Boston,
Massachusetts (Hofmann, Otto); Department of
Psychiatry, University of Minnesota, Minneapolis,
(Kushner); Department of Psychiatry, Washington
University School of Medicine, St Louis, Missouri
(Lenze); University of Louisville, Louisville,
Kentucky (Levinson); School of Medicine, Griffith
University, Brisbane, Queensland, Australia
(McConnell, Siewert-Siegmund); Department of
Psychiatry and Psychotherapy, Campus Charité
Mitte, Charité – University Medicine Berlin, Berlin,
Germany (Plag, Ströhle); Department of Psychiatry,
Rush University Medical Center, Chicago, Illinois
(Pollack); McLean Hospital, Belmont,
Massachusetts (Ressler); Department of
Psychological and Brain Sciences, Washington
University School of Medicine, St Louis, Missouri
(Rodebaugh); Department of Psychiatry and
Behavioral Sciences, Tulane University School of
Medicine, NewOrleans, Louisiana (Scheeringa);
Institute for Mental Health Research, Department
of Psychology, The University of Texas, Austin
(Smits); Department of Pediatrics, University of
South Florida, Tampa (Storch); Rogers Behavioral
Health, Tampa, Florida (Storch); NewMexico
Veterans Affairs Health Care System, Albuquerque,
NewMexico (Tart); The Institute of Living, Hartford,
Connecticut (Tolin); Yale University School of
Medicine, NewHaven, Massachusetts (Tolin);
Department of Human Development and Family
Studies, Iowa State University, Ames (Weems);
Cuny School of Public Health, City University of
New York Graduate School of Public Health and
Health Policy, New York (Wyka).
Author Contributions:Drs Fernández de la Cruz
and Rosenfield had full access to all the data in the
study and take responsibility for the integrity of the
data and the accuracy of the data analyses.
Drs Mataix-Cols and Fernández de la Cruz served as
co-first authors and contributed equally to the
work.
Concept and design:Mataix-Cols, Fernández de la
Cruz, Andersson, Davis, Rück.
Acquisition, analysis, or interpretation of data:
Mataix-Cols, Fernández de la Cruz, Monzani,
Rosenfield, Pérez-Vigil, Frumento, Davis, Rück.
Drafting of the manuscript:Mataix-Cols, Fernández
de la Cruz, Rosenfield.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Fernández de la Cruz,
Rosenfield, Frumento.
Administrative, technical, or material support:
Monzani, Pérez-Vigil.
Supervision:Mataix-Cols, Fernández de la Cruz.
Group Information:Members of the DCS Anxiety
Consortium include all authors listed above as well
as the following: Margaret Altemus, MD
(Department of Psychiatry, Weill Cornell Medical
College, New York, New York); Page Anderson, PhD
(Department of Psychology, Georgia State
University, Atlanta); Judith Cukor, PhD (Department
of Psychiatry, Weill Cornell Medical College, New
York, New York); Claudia Finck, MD (Department of
Psychiatry and Psychotherapy, Campus Charité
Mitte, Charité–University Medicine Berlin, Berlin,
Germany); Gary R. Geffken, PhD (Department of
Psychiatry, University of Florida, Gainesville);
Fabian Golfels (Department of Psychiatry and
Psychotherapy, Campus Charité Mitte, Charité–
University Medicine Berlin, Berlin, Germany);
Wayne K. Goodman, MD (Department of
Neuroscience, Icahn School of Medicine at Mount
Sinai, New York, New York); Cassidy Gutner, PhD
(Department of Psychiatry, Boston University
School of Medicine, Boston, Massachusetts); Isobel
Heyman, MBBS, PhD (Great Ormond Street
Hospital for Children, University College London,
London, United Kingdom); Tanja Jovanovic, PhD
(Department of Psychiatry and Behavioral Sciences,
Emory University School of Medicine, Atlanta,
Georgia); Adam B. Lewin, PhD (Departments of
Pediatrics and Behavioral Neurosciences, University
of South Florida, Tampa); Joseph P. McNamara, PhD
(Department of Psychiatry, University of Florida,
Gainesville); Tanya K. Murphy, MD (Departments of
Pediatrics and Behavioral Neurosciences, University
of South Florida, Tampa); Seth Norrholm, PhD
(Department of Psychiatry and Behavioral Sciences,
Emory University School of Medicine, Atlanta,
Georgia); and Paul Thuras, PhD (Minneapolis
Veterans Affairs Health Care System, Minneapolis,
Minnesota).
Conflict of Interest Disclosures: All authors with
the exception of Drs Fernández de la Cruz (joint
first author), Frumento (independent statistician),
and Pérez-Vigil (independent systematic reviewer)
were investigators on 1 or more of the original
randomized clinical trials that contributed data to
the individual participant data and secured grant
funding for these trials. Drs Davis and Ressler hold
patents for the use of D-cycloserine and
psychotherapy, targeting PAC1 receptor for
extinction, targeting tachykinin 2 for prevention of
fear, and targeting angiotensin to improve
extinction of fear. Dr Ressler is also founding
member of Extinction Pharmaceuticals to develop
D-cycloserine to augment the effectiveness of
psychotherapy, for which he has received no equity
or incomewithin the past 3 years. Dr Otto reports
serving in the past 3 years as a paid consultant for
MicroTransponder Inc, Concert Pharmaceuticals,
and ProPhase, providing expert consensus opinion
for Otsuka Pharmaceuticals, receiving royalty
support for use of the SIGH-A from ProPhase, and
receiving book royalties fromOxford University
Press, Routledge, and Springer. Dr Pollack serves as
consultant/advisor for Clintara, Edgemont
Pharmaceuticals, and Palo Alto Health Sciences.
Dr Pollack reports a patent for SIGH-A and royalties
for SAFER interviews. Dr Pollack’s equity disclosure
includes DoyenMedical, Medavante, Mensante
Corporation, Mindsite, and Targia Pharmaceuticals.
Dr Ressler reports current or past funds from the
National Institute of Mental Health, the Howard
Hughes Medical Institute, the Brain and Behavior
Research Foundation, and BurroughsWellcome
Fund. In addition, Dr Ressler is on the scientific
advisory boards for Resilience Therapeutics,
Sheppard Pratt-Lieber Research Institute, Laureate
Institute for Brain Research, The Army STARRS
Project, and the Anxiety and Depression
Association of America. Dr Rothbaum owns equity
in Virtually Better Inc, which creates virtual
environments. The terms of this arrangement have
been reviewed and approved by Emory University
in accordance with its conflict of interest policies.
Dr Storch reports royalties from Elsevier, the
American Psychological Association, Springer, Wiley
Inc, and Lawrence Erlbaum and is a consultant for
Ruijin Hospital and Rogers Memorial Hospital.
Dr Ströhle serves as speaker honoraria for
AstraZeneca, Boehringer Ingelheim, Bristol-Myers
Squibb, Eli Lilly & Co, Lundbeck, Pfizer, Wyeth, and
UCB and was a consultant for Actelion. Dr Ströhle’s
educational grants were given by the
Stifterverband für die DeutscheWissenschaft, the
Berlin Brandenburgische Akademie der
Research Original Investigation D-Cycloserine Augmentation of Cognitive Behavior Therapy
E8 JAMAPsychiatry Published online January 25, 2017 (Reprinted) jamapsychiatry.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/0/ by a Boston University User  on 01/25/2017
Copyright 2017 American Medical Association. All rights reserved.
Wissenschaften, the Boehringer Ingelheim Fonds,
the Eli Lilly International Foundation, Janssen-Cilag,
Pfizer, and Eli Lilly & Co. DrWilhelm has received
research funding and salary support from the
National Institutes of Health, and she has also
received research support in the form of free
medication andmatching placebo from Forest
Laboratories for clinical trials funded by the
National Institutes of Health. DrWilhelm is a
presenter for theMassachusetts General Hospital
Psychiatry Academy in educational programs
supported through independent medical education
grants from pharmaceutical companies; she has
received royalties from Elsevier Publications,
Guilford Publications, and NewHarbinger
Publications fromOxford University Press.
Dr Wilhelm has also received speaking honorarium
from various academic institutions and
foundations, including the International Obsessive
Compulsive Disorder Foundation and the Tourette’s
Syndrome Association. In addition, she received
payment from the Association for Behavioral and
Cognitive Therapies for her role as Associate Editor
for the journal Behavior Therapy as well as from
JohnWiley & Sons Inc for her role as Associate
Editor on the journal Depression and Anxiety.
Dr Wilhelm has also received salary support from
Novartis. No other disclosures were reported.
Funding/Support: Australian Rotary Health
Research Fund (Farrell); Brain and Behavior
Research Foundation Independent Investigator
Award (Scheeringa); Brain and Behavior Research
Foundation, Robidoux Foundation Young
Investigator Award (Storch); DeWitt-Wallace Fund,
New York Community Trust (Difede); German
Federal Ministry of Education and Research
(Siegmund); Hartford Hospital (Nave); International
OCD Foundation (Kushner; Storch); Massachusetts
General Hospital (Wilhelm); National Health and
Medical Research Council (Guastella); National
Institutes of Health (Storch); National Institute for
Health Research (NIHR) Specialist Biomedical
Research Centre for Mental Health (Mataix-Cols);
National Institute of Mental Health (Gutner;
Hofmann; Ressler; Rodebaugh; Rosenfield;
Rothbaum; Scheeringa; Tart); Stichting Achmea
Slachtoffer en Samenleving and Vereniging tot
Christelijke Verzorging van Geestes- en
Zenuwzieken (VanMinnen); and Swedish Research
Council, Stockholm County Council (Rück).
Dr Rosenfield reports funds from the National
Institute on Drug Abuse. Ms Pérez-Vigil is
supported by a grant from the Alicia Koplowitz
Foundation. Dr Hofmann reports funds from the
National Center for Complementary and Integrative
Health (R01AT007257), the McDonnell Foundation
21st Century Science Initiative in Understanding
Human Cognition – Special Initiative, and the
Department of the Army. Dr Kushner reports funds
from the National Institute on Alcohol Abuse and
Alcoholism (R01AA015069). Dr Lenze reports
funds from Takeda, Lundbeck, and Janssen.
Dr Levinson reports funds from the National
Institutes of Health (5T32DA007261-17).
Dr McConnell reports funds from the Rotary Mental
Health Research Fund. Dr Pollack reports funds
from the National Institutes of Health, Janssen, and
Edgemont. Dr Rodebaugh reports current funds
from theMcDonnell Center for Systems
Neuroscience. Dr Scheeringa reports funds from a
2009 National Alliance for Research on
Schizophrenia and Depression Independent
Investigator Award. Dr Smits reports funds from the
National Institute on Drug Abuse. Dr Storch reports
funds from the Agency for Healthcare Research and
Quality and All Children’s Hospital Research
Foundation. Dr Ströhle reports funds from the
German Federal Ministry of Education and
Research, the German Research Foundation, the
European Commission, and Lundbeck. DrWaters
reports funds from the Rotary Mental Health
Research Fund Australia. Dr Rück is supported by a
grant from the Swedish Research Council
(K2013-61P-22168). Dr Murphy reports funds from
a National Institutes of Health K23 grant.
Role of the Funder/Sponsor: The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of themanuscript; and decision to submit
themanuscript for publication.
Additional Contributions:We thank Anna Halisch,
BSc (Charité-Universitätsmedizin, Berlin, Germany),
for her contribution as a therapist in the Siegmund
et al study.43 She was not compensated for her
work.
Acknowledgements: The study protocol was
registered with PROSPERO (CRD42015025359)
and it is accessible from http://www.crd.york.ac.uk
/PROSPERO/display_record.asp?ID=
CRD42015025359.
REFERENCES
1. Kessler RC, Angermeyer M, Anthony JC, et al.
Lifetime prevalence and age-of-onset distributions
of mental disorders in theWorld Health
Organization’s World Mental Health Survey
Initiative.World Psychiatry. 2007;6(3):168-176.
2. Murray CJ, Richards MA, Newton JN, et al. UK
health performance: findings of the Global Burden
of Disease Study 2010. Lancet. 2013;381(9871):
997-1020.
3. American Psychiatric Association. Practice
Guideline for the Treatment of Patients With Panic
Disorder. Arlington, VA: American Psychiatric
Association; 2009.
4. American Psychiatric Association. Practice
Guideline for the Treatment of Patients With
Obsessive-Compulsive Disorder. Arlington, VA:
American Psychiatric Association; 2007.
5. American Psychiatric Association. Practice
Guideline For the Treatment of PatientsWith Acute
Stress Disorder and Posttraumatic Stress Disorder.
Arlington,VA:AmericanPsychiatric Association; 2004.
6. National Institute for Health and Care
Excellence. Social Anxiety Disorder: Recognition,
Assessment, and Treatment - National Clinical
Guideline Number 159. London, UK: The British
Psychological Society & The Royal College of
Psychiatrists; 2013.
7. National Institute for Health andCare Excellence.
Obsessive-Compulsive Disorder: Core Interventions in
the Treatment of Obsessive-Compulsive Disorder and
BodyDysmorphic Disorder - National Clinical Practice
Guideline Number 31. London, UK: TheBritish
Psychological Society & TheRoyal College of
Psychiatrists; 2006.
8. National Institute for Health and Care
Excellence. Generalised Anxiety Disorder in Adults:
Management in Primary, Secondary, and
Community Care - National Clinical Guideline
Number 113. London, UK: The British Psychological
Society & The Royal College of Psychiatrists; 2011.
9. National Institute for Health and Care
Excellence. Post-Traumatic Stress Disorder: The
Management of PTSD in Adults and Children in
Primary and Secondary Care - National Clinical
Guideline Number 26. London, UK: The British
Psychological Society & The Royal College of
Psychiatrists; 2005.
10. Baldwin DS, Anderson IM, Nutt DJ, et al.
Evidence-based pharmacological treatment of
anxiety disorders, post-traumatic stress disorder
and obsessive-compulsive disorder: a revision of
the 2005 guidelines from the British Association for
Psychopharmacology. J Psychopharmacol. 2014;28
(5):403-439.
11. Hofmann SG, Sawyer AT, Korte KJ, Smits JA.
Is it beneficial to add pharmacotherapy to
cognitive-behavioral therapy when treating anxiety
disorders? a meta-analytic review. Int J Cogn Ther.
2009;2(2):160-175.
12. Furukawa TA, Watanabe N, Churchill R.
Psychotherapy plus antidepressant for panic
disorder with or without agoraphobia: systematic
review. Br J Psychiatry. 2006;188:305-312.
13. OttoMW,McHughRK, Kantak KM. Combined
pharmacotherapy and cognitive-behavioral therapy
for anxiety disorders:medication effects,
glucocorticoids, and attenuated treatment
outcomes.Clin Psychol (NewYork). 2010;17(2):91-103.
14. Marks IM, Swinson RP, Başoğlu M, et al.
Alprazolam and exposure alone and combined in
panic disorder with agoraphobia: a controlled study
in London and Toronto. Br J Psychiatry. 1993;162:
776-787.
15. Barlow DH, Gorman JM, Shear MK,Woods SW.
Cognitive-behavioral therapy, imipramine, or their
combination for panic disorder: a randomized
controlled trial. JAMA. 2000;283(19):2529-2536.
16. Davis M, Ressler K, Rothbaum BO, Richardson
R. Effects of D-cycloserine on extinction: translation
from preclinical to clinical work. Biol Psychiatry.
2006;60(4):369-375.
17. Dunlop BW,Mansson E, GerardiM.
Pharmacological innovations for posttraumatic stress
disorder andmedication-enhanced psychotherapy.
Curr PharmDes. 2012;18(35):5645-5658.
18. Ressler KJ, Rothbaum BO, Tannenbaum L, et al.
Cognitive enhancers as adjuncts to psychotherapy:
use of D-cycloserine in phobic individuals to
facilitate extinction of fear. Arch Gen Psychiatry.
2004;61(11):1136-1144.
19. Hofmann SG, Meuret AE, Smits JA, et al.
Augmentation of exposure therapy with
D-cycloserine for social anxiety disorder. Arch Gen
Psychiatry. 2006;63(3):298-304.
20. Kushner MG, Kim SW, Donahue C, et al.
D-cycloserine augmented exposure therapy for
obsessive-compulsive disorder. Biol Psychiatry.
2007;62(8):835-838.
21. Hofmann SG, Smits JA, Rosenfield D, et al.
D-Cycloserine as an augmentation strategy with
cognitive-behavioral therapy for social anxiety
disorder. Am J Psychiatry. 2013;170(7):751-758.
22. Andersson E, Hedman E, Enander J, et al.
D-Cycloserine vs placebo as adjunct to cognitive
behavioral therapy for obsessive-compulsive
disorder and interaction with antidepressants:
a randomized clinical trial. JAMA Psychiatry. 2015;72
(7):659-667.
D-Cycloserine Augmentation of Cognitive Behavior Therapy Original Investigation Research
jamapsychiatry.com (Reprinted) JAMAPsychiatry Published online January 25, 2017 E9
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/0/ by a Boston University User  on 01/25/2017
Copyright 2017 American Medical Association. All rights reserved.
23. BontempoA, Panza KE, BlochMH.D-cycloserine
augmentation of behavioral therapy for the
treatment of anxiety disorders: ameta-analysis. J Clin
Psychiatry. 2012;73(4):533-537.
24. Rodrigues H, Figueira I, Lopes A, et al. Does
D-cycloserine enhance exposure therapy for
anxiety disorders in humans? a meta-analysis. PLoS
One. 2014;9(7):e93519.
25. Ori R, Amos T, Bergman H, Soares-Weiser K,
Ipser JC, Stein DJ. Augmentation of cognitive and
behavioural therapies (CBT) with d-cycloserine for
anxiety and related disorders. Cochrane Database
Syst Rev. 2015;5(5):CD007803.
26. Xia J, Du Y, Han J, Liu G, Wang X. D-cycloserine
augmentation in behavioral therapy for
obsessive-compulsive disorder: a meta-analysis.
Drug Des Devel Ther. 2015;9:2101-2117.
27. Otto MW, KredlowMA, Smits JA, et al.
Enhancement of psychosocial treatment with
d-cycloserine: models, moderators, and future
directions. Biol Psychiatry. 2016;80(4):274-283.
28. Skolnick P. Antidepressants for the new
millennium. Eur J Pharmacol. 1999;375(1-3):31-40.
29. Werner-Seidler A, Richardson R. Effects of
D-cycloserine on extinction: consequences of prior
exposure to imipramine. Biol Psychiatry. 2007;62
(10):1195-1197.
30. Burghardt NS, Sigurdsson T, Gorman JM,
McEwen BS, LeDoux JE. Chronic antidepressant
treatment impairs the acquisition of fear extinction.
Biol Psychiatry. 2013;73(11):1078-1086.
31. Stewart LA, ClarkeM, RoversM, et al;
PRISMA-IPDDevelopment Group. Preferred
reporting items for systematic review and
meta-analyses of individual participant data: the
PRISMA-IPDstatement. JAMA. 2015;313(16):1657-1665.
32. Tierney JF, Vale C, Riley R, et al. Individual
participant data (IPD) meta-analyses of randomised
controlled trials: guidance on their use. PLoS Med.
2015;12(7):e1001855.
33. Higgins JP, Altman DG, Gøtzsche PC, et al;
Cochrane Bias Methods Group; Cochrane Statistical
Methods Group. The Cochrane Collaboration’s tool
for assessing risk of bias in randomised trials. BMJ.
2011;343:d5928.
34. Higgins JPT, Altman DG; Cochrane Statistical
Methods Group and the Cochrane Bias Methods
Group. Assessing risk of bias in included studies. In:
Higgins J, Green S, eds. Cochrane Handbook of
Systematic Reviews of Interventions. West Sussex,
United Kingdom: The Cochrane Collaboration and
JohnWiley & Sons Ltd; 2008.
35. Raudenbush SW, Xiao-Feng L. Effects of study
duration, frequency of observation, and sample size
on power in studies of group differences in
polynomial change. Psychol Methods. 2001;6(4):
387-401.
36. Feingold A. Effect sizes for growth-modeling
analysis for controlled clinical trials in the same
metric as for classical analysis. Psychol Methods.
2009;14(1):43-53.
37. Nave AM, Tolin DF, Stevens MC. Exposure
therapy, D-cycloserine, and functional magnetic
resonance imaging in patients with snake phobia:
a randomized pilot study. J Clin Psychiatry. 2012;73
(9):1179-1186.
38. Gutner CA, Weinberger J, Hofmann SG. The
effect of D-cycloserine on subliminal cue exposure
in spider fearful individuals. Cogn Behav Ther. 2012;
41(4):335-344.
39. Tart CD, Handelsman PR, Deboer LB, et al.
Augmentation of exposure therapy with
post-session administration of D-cycloserine.
J Psychiatr Res. 2013;47(2):168-174.
40. Guastella AJ, RichardsonR, LovibondPF, et al.
A randomized controlled trial of D-cycloserine
enhancement of exposure therapy for social anxiety
disorder.Biol Psychiatry. 2008;63(6):544-549.
41. Rodebaugh TL, Levinson CA, Lenze EJ.
A high-throughput clinical assay for testing drug
facilitation of exposure therapy. Depress Anxiety.
2013;30(7):631-637.
42. Otto MW, Tolin DF, Simon NM, et al. Efficacy of
d-cycloserine for enhancing response to
cognitive-behavior therapy for panic disorder. Biol
Psychiatry. 2010;67(4):365-370.
43. Siegmund A, Golfels F, Finck C, et al.
D-cycloserine does not improve but might slightly
speed up the outcome of in-vivo exposure therapy
in patients with severe agoraphobia and panic
disorder in a randomized double blind clinical trial.
J Psychiatr Res. 2011;45(8):1042-1047.
44. Storch EA, Merlo LJ, BengtsonM, et al.
D-cycloserine does not enhance exposure-response
prevention therapy in obsessive-compulsive
disorder. Int Clin Psychopharmacol. 2007;22(4):
230-237.
45. Wilhelm S, Buhlmann U, Tolin DF, et al.
Augmentation of behavior therapy with
D-cycloserine for obsessive-compulsive disorder.
Am J Psychiatry. 2008;165(3):335-341.
46. Storch EA, Murphy TK, GoodmanWK, et al.
A preliminary study of D-cycloserine augmentation
of cognitive-behavioral therapy in pediatric
obsessive-compulsive disorder. Biol Psychiatry.
2010;68(11):1073-1076.
47. Farrell LJ, Waters AM, BoschenMJ, et al.
Difficult-to-treat pediatric obsessive-compulsive
disorder: feasibility and preliminary results of a
randomized pilot trial of D-cycloserine-augmented
behavior therapy. Depress Anxiety. 2013;30(8):
723-731.
48. Mataix-Cols D, Turner C, Monzani B, et al.
Cognitive-behavioural therapy with post-session
D-cycloserine augmentation for paediatric
obsessive-compulsive disorder: pilot randomised
controlled trial. Br J Psychiatry. 2014;204(1):77-78.
49. de Kleine RA, Hendriks GJ, Kusters WJ,
Broekman TG, vanMinnen A. A randomized
placebo-controlled trial of D-cycloserine to enhance
exposure therapy for posttraumatic stress disorder.
Biol Psychiatry. 2012;71(11):962-968.
50. Litz BT, Salters-Pedneault K, SteenkampMM,
et al. A randomized placebo-controlled trial of
D-cycloserine and exposure therapy for
posttraumatic stress disorder. J Psychiatr Res. 2012;
46(9):1184-1190.
51. Scheeringa MS, Weems CF. Randomized
placebo-controlled D-cycloserine with cognitive
behavior therapy for pediatric posttraumatic stress.
J Child Adolesc Psychopharmacol. 2014;24(2):69-77.
52. Difede J, Cukor J, Wyka K, et al. D-cycloserine
augmentation of exposure therapy for
post-traumatic stress disorder: a pilot randomized
clinical trial. Neuropsychopharmacology. 2014;39
(5):1052-1058.
53. RothbaumBO, PriceM, Jovanovic T, et al.
A randomized, double-blind evaluation of
D-cycloserine or alprazolam combinedwith virtual
reality exposure therapy for posttraumatic stress
disorder in Iraq andAfghanistanWar veterans.Am J
Psychiatry. 2014;171(6):640-648.
54. Tabachnick B, Fidell L. Using Multivariate
Statistics. 6th ed. Boston,MA: Allyn &Bacon/Pearson
Education; 2013.
55. Chasson GS, Buhlmann U, Tolin DF, et al. Need
for speed: evaluating slopes of OCD recovery in
behavior therapy enhanced with d-cycloserine.
Behav Res Ther. 2010;48(7):675-679.
56. Hofmann SG. D-cycloserine for treating anxiety
disorders:making good exposures better and bad
exposuresworse.Depress Anxiety. 2014;31(3):175-177.
57. Hofmann SG, Otto MW, Pollack MH, Smits JA.
D-cycloserine augmentation of cognitive behavioral
therapy for anxiety disorders: an update. Curr
Psychiatry Rep. 2015;17(1):532.
58. Smits JA, Rosenfield D, Otto MW, et al.
D-cycloserine enhancement of exposure therapy
for social anxiety disorder depends on the success
of exposure sessions. J Psychiatr Res. 2013;47
(10):1455-1461.
59. Stewart LA, Clarke MJ; CochraneWorking
Group. Practical methodology of meta-analyses
(overviews) using updated individual patient data.
Stat Med. 1995;14(19):2057-2079.
60. Norberg MM, Krystal JH, Tolin DF.
Ameta-analysis of D-cycloserine and the facilitation
of fear extinction and exposure therapy. Biol
Psychiatry. 2008;63(12):1118-1126.
61. Smits JA, Rosenfield D, Otto MW, et al.
D-cycloserine enhancement of fear extinction is
specific to successful exposure sessions: evidence
from the treatment of height phobia. Biol Psychiatry.
2013;73(11):1054-1058.
62. Smits JA, Rosenfield D, Davis ML, et al.
Yohimbine enhancement of exposure therapy for
social anxiety disorder: a randomized controlled
trial. Biol Psychiatry. 2014;75(11):840-846.
63. Telch MJ, Bruchey AK, Rosenfield D, et al.
Effects of post-session administration of methylene
blue on fear extinction and contextual memory in
adults with claustrophobia. Am J Psychiatry. 2014;
171(10):1091-1098.
64. Hofmann SG, Carpenter JK, Otto MW,
Rosenfield D, Smits JA, Pollack MH. Dose timing of
D-cycloserine to augment cognitive behavioral
therapy for social anxiety: study design and
rationale. Contemp Clin Trials. 2015;43:223-230.
65. Davis ML, Witcraft SM, Smits JAJ, et al.
D-Cycloserine augmentation of exposure therapy:
review and new directions.Qual Prim Care. 2016;24
(1):30-32.
Research Original Investigation D-Cycloserine Augmentation of Cognitive Behavior Therapy
E10 JAMAPsychiatry Published online January 25, 2017 (Reprinted) jamapsychiatry.com
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/0/ by a Boston University User  on 01/25/2017
